Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for the neoadjuvant treatment of triple negative breast cancer
 
Status In progress
Process STA 2018
ID number 1500

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 August 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
04 January 2019 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab plus chemotherapy as a neo-adjuvant therapy in patients with previously untreated locally advanced non-metastatic triple negative breast cancer. I am writing to advise that following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-July 2019.
15 October 2018 - 12 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 June 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance